Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > REGULATORY
REGULATORY
- MHLW Sets Interim Nitrosamine Limit for Atomoxetine, 5 Generic Makers Launch Fresh Recalls
October 23, 2025
- New Health Minister Pledges to Strengthen Japan’s Drug Discovery Capabilities
October 23, 2025
- LDP’s Nagasaka Appointed Senior Vice Health Minister; Niki to Stay On
October 23, 2025
- Public-Private WG to Compile Industry Proposals on Drug Pricing Reforms at Next Session
October 23, 2025
- MHLW Orders Label Revisions for Amitiza, Shingrix, and More
October 23, 2025
- Takaichi Faces Tough Balancing Act on Healthcare, Nursing Reform
October 22, 2025
- LDP’s Takaichi Elected as Japan’s First Female Prime Minister
October 22, 2025
- LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
October 21, 2025
- No Objections to Expanding Reimbursement Incentives for Biosimilars: Chuikyo
October 20, 2025
- Payers, Providers Clash over Fate of Fee Premiums for Generic Use
October 20, 2025
- MHLW Panel Launches Full Debate on Drug Coverage Reform; LLPs, Biologics, OTC-Like Meds in Focus
October 17, 2025
- GSK’s Blenrep, BMS’s Inrebic Absent from October Listing Roster
October 17, 2025
- Shionogi/Sage’s Depression Drug Up for MHLW Panel Review on Oct. 30
October 17, 2025
- SanBio’s Akuugo Nears Shipment with MHLW Panel Backing; Sakigake Tag OK’ed for Bayer Gene Therapies
October 17, 2025
- Chuikyo Clears Listing for Yorvipath and More Drugs; Zero Premium Rule Weighs Yet Again
October 16, 2025
- Japan to Clarify Criteria for Upward Price Adjustments under CEA Scheme
October 16, 2025
- Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
- Listing OK’ed for Krystal’s Vyjuvek Gel, Japan’s First Topical Gene Therapy
October 16, 2025
- Chuikyo Urges Stricter Pricing Rules for Conditionally Approved Regenerative Medicines
October 16, 2025
- Label Expansion of Braftovi, Augtyro, Lunsumio SC Up for MHLW Panel Review
October 16, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…